BMY · XBRL financial data

Bristol-Myers Squibb Company financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (BMY's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	42,518	46,385	46,159	45,006	48,300	48,194
Cost of goods and services sold	11,773	9,940	10,137	10,693	13,968	13,936
Gross profit	30,745	—	—	—	—	—
Research and development	11,143	11,354	9,509	9,299	11,159	9,951
Selling, general and administrative	7,661	7,690	7,814	7,772	8,414	7,267
Interest income	121	39	171	449	478	586
Interest expense	1,420	1,334	1,232	1,166	1,947	1,891
Other income (expense)	2,314	720	(576)	1,158	(893)	(674)
Income tax expense (benefit)	2,124	1,084	1,368	400	554	2,272
Net income (loss)	(9,015)	6,994	6,327	8,025	(8,948)	7,054
Earnings per share, basic USD per share	(3.99)	3.15	2.97	3.88	(4.41)	3.47
Earnings per share, diluted USD per share	(3.99)	3.12	2.95	3.86	(4.41)	3.46
Weighted average shares, basic millions of shares	2,258	2,221	2,130	2,069	2,027	2,034
Weighted average shares, diluted millions of shares	2,258	2,245	2,146	2,078	2,027	2,039

Fiscal years (BMY's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	14,546	13,979	9,123	11,464	10,346	10,209
Marketable securities	1,285	2,987	130	816	513	464
Marketable securities, non-current	433	0	0	364	320	396
Accounts receivable	7,219	7,979	8,151	8,882	9,012	9,592
Inventory	2,074	2,095	2,339	2,662	2,557	2,690
Total current assets	30,192	33,262	27,273	31,770	29,780	29,390
Property and equipment, net	5,886	6,049	6,255	6,646	7,136	7,543
Right-of-use asset	859	919	1,220	1,390	1,224	1,582
Goodwill	20,547	20,502	21,149	21,169	21,719	21,754
Total assets	118,481	109,314	96,820	95,159	92,603	90,038
Accounts payable	2,713	2,949	3,040	3,259	3,602	3,575
Commercial paper	—	—	—	0	—	—
Current portion of long-term debt	2,000	4,764	3,897	2,873	1,828	1,977
Total current liabilities	19,080	21,868	21,890	22,262	23,774	23,417
Long-term debt	48,336	39,605	35,056	36,653	47,603	42,850
Lease liability, non-current	833	874	1,261	1,530	1,370	1,826
Total liabilities	80,599	73,308	65,702	65,674	76,215	71,533
Retained earnings	21,281	23,820	25,503	28,766	14,912	16,896
Total stockholders' equity	37,822	35,946	31,061	29,430	16,335	18,473
Total liabilities and equity	118,481	109,314	96,820	95,159	92,603	90,038
Common shares outstanding (cover page) millions of shares	2,240	2,180	2,099	2,022	2,029	2,036

Fiscal years (BMY's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(9,015)	6,994	6,327	8,025	(8,948)	7,054
Stock-based compensation	779	583	457	518	507	553
Depreciation and amortization	10,380	10,686	10,276	9,760	9,600	4,011
Net cash from operating activities	14,052	16,207	13,066	13,860	15,190	14,156
Purchases of property and equipment	753	973	1,118	1,209	1,248	1,311
Net cash from investing activities	(10,859)	(538)	(1,062)	(2,295)	(21,352)	(4,132)
Share repurchases	1,546	6,287	8,001	5,155	0	0
Dividends paid	4,075	4,396	4,634	4,744	4,863	5,045
Proceeds from long-term debt	6,945	0	5,926	4,455	12,883	5,740
Repayments of long-term debt	2,750	6,022	11,431	3,879	2,873	10,940
Net cash from financing activities	(1,151)	(16,224)	(16,962)	(9,416)	5,127	(10,348)
Net change in cash	2,153	(657)	(4,991)	2,194	(1,172)	(129)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Quarter
Bristol Myers Squibb	9,574	13,069	4,181*	2.0B	Q3 FY26 10-QSep 30, 2026
Gilead Sciences	6,437	8,300	5,035*	1.2B	Q3 FY26 10-QSep 30, 2026
Vertex Pharmaceuticals	4,979	3,441	643*	253.5M	Q3 FY26 10-QSep 30, 2026
Zoetis	1,476	2,468	655*	413.2M	Q2 FY26 10-QJun 30, 2026
Pfizer	1,824	16,583	5,375*	5.7B	Q3 FY26 10-QSep 27, 2026
Amgen	13,190	10,365	4,241*	540.9M	Q3 FY26 10-QSep 30, 2026
Regeneron Pharmaceuticals	3,659	5,116	1,783*	not reported	Q3 FY26 10-QSep 30, 2026
Merck	9,550	18,085	6,558*	2.5B	Q3 FY26 10-QSep 30, 2026
Idexx Laboratories	198	1,214	450*	78.8M	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.